Lung Cancer: A Clear Guide to Diagnosis, Staging and Treatment
Understanding a lung cancer diagnosis begins with three questions: What type is it? How far has it spread? Which treatments fit its specific features? This guide explains the evidence in plain language.
Lung cancer is not one single disease. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their behavior and treatment can differ substantially. An accurate diagnosis, stage and—where appropriate—biomarker results help guide care.
What Is Lung Cancer?
Lung cancer develops when abnormal cells in the lungs grow without normal control. These cells may form a tumor, invade nearby tissue or spread to distant organs. Spread to another organ is called metastasis.
The most common type. Major subtypes include adenocarcinoma and squamous cell carcinoma. Surgery, radiation, chemotherapy, immunotherapy and biomarker-directed targeted treatments may be appropriate in different situations.
Usually grows and spreads more rapidly. Chemotherapy, immunotherapy and radiation are important treatment options; surgery is used only in carefully selected early cases.
Smoking is the leading preventable risk factor, but lung cancer also occurs in people who have never smoked. Other risks include radon, secondhand smoke, some occupational exposures and air pollution.
Symptoms: What Should You Watch For?
Early lung cancer may cause no symptoms. Possible signs include a persistent or changing cough, coughing up blood, breathlessness, chest pain, recurrent chest infections, hoarseness, unexplained weight loss and fatigue.
Many of these symptoms have other causes. Persistent or worsening symptoms deserve assessment. Coughing up blood should be evaluated promptly; severe difficulty breathing requires urgent care.
How Is Lung Cancer Diagnosed?
Doctors combine scans, tissue examination and sometimes molecular tests. The precise sequence depends on the location of the suspected tumor and the patient’s health.
- Chest CT: Detailed images of the lungs and nearby structures.
- Biopsy: A sample of cells or tissue examined to confirm the diagnosis and identify the cancer type.
- Bronchoscopy: A camera-guided examination of the airways that can collect samples.
- PET/CT: Helps investigate possible spread; suspicious findings sometimes need confirmation.
- Brain MRI: Used when indicated by the type, stage or symptoms.
- Lymph node sampling: Procedures such as endobronchial ultrasound-guided biopsy can improve staging accuracy.
Imaging identifies abnormalities and helps estimate their extent. Pathology examines cells or tissue. A treatment plan often needs information from both.
Understanding Lung Cancer Stages
Staging describes how far cancer has spread. NSCLC is generally staged using the TNM system: T describes the primary tumor, N describes regional lymph nodes, and M describes spread to distant sites.
Stage I: Generally localized cancer without regional lymph node involvement.
Stage II: May involve a larger tumor, nearby structures or certain nearby lymph nodes.
Stage III: More locally advanced disease, often involving lymph nodes or structures within the chest.
Stage IV: Distant spread or other findings meeting the criteria for metastatic disease.
These are simplified descriptions. The exact TNM classification and edition used determine the formal stage.
SCLC is often grouped into limited-stage and extensive-stage disease, although TNM staging may also be used. Limited-stage disease is generally confined to an area that can be covered by an acceptable radiation treatment field.
Localized cancer may be treated with the goal of cure. More advanced disease may require combinations of local and whole-body treatments. Stage is one of the most important factors in selecting an appropriate approach.
Biomarkers: Why Molecular Testing Matters
Some NSCLC tumors carry genetic alterations that make them sensitive to particular targeted medicines. Biomarker testing looks for these features. It can be especially important in advanced NSCLC, and testing may also guide treatment in selected earlier-stage settings.
- EGFR, ALK and ROS1: Certain alterations can identify targeted treatment options.
- BRAF, MET, RET, NTRK, KRAS and HER2 (ERBB2): Specific changes may be relevant to approved therapies or clinical trials.
- PD-L1: A protein measurement that helps inform some immunotherapy decisions.
For eligible patients, molecular results can guide the use of medicines directed at a tumor’s specific alteration.
Results depend on the exact alteration, cancer stage, previous therapy and the available medicine. PD-L1 is not a perfect predictor of immunotherapy benefit.
Testing may use tumor tissue or a blood sample that detects circulating tumor DNA. A negative blood test does not always exclude a targetable alteration, and tissue testing may still be necessary.
How Is Lung Cancer Treated?
Treatment depends on NSCLC versus SCLC, stage, molecular findings, lung function, overall health and personal goals. Different treatments may be combined or used in sequence.
Surgery can be a potentially curative option for selected early-stage NSCLC. It removes the tumor and an appropriate amount of surrounding lung tissue, with lymph node assessment when indicated.
Radiation damages cancer cells using focused energy. It may be used with curative intent, together with chemotherapy or to relieve symptoms. Stereotactic body radiation therapy (SBRT) can be an option for selected early-stage tumors when surgery is unsuitable.
Chemotherapy acts against rapidly dividing cells. It may be given before surgery, after surgery, alongside radiation or for advanced disease. It remains a major part of SCLC treatment.
Some immunotherapies block immune checkpoints, helping the immune system attack cancer. They can improve outcomes in selected NSCLC and SCLC settings, but may also cause serious immune-related side effects.
Targeted medicines act against particular molecular alterations. For patients whose tumors have actionable changes, targeted treatment may be preferable to other first-line options. Eligibility varies by alteration, stage and treatment history.
How Does Treatment Change by Stage?
Surgery or focused radiation may be used. Selected patients also benefit from chemotherapy, immunotherapy or targeted therapy before or after surgery.
Stage III NSCLC may require chemotherapy and radiation, sometimes followed by immunotherapy or a targeted medicine. Surgery is an option in selected cases.
For most metastatic NSCLC, treatment is systemic: targeted therapy, immunotherapy, chemotherapy or combinations. The usual aim is to control disease, prolong life and preserve well-being. Some people with limited metastatic disease may also benefit from carefully selected local treatments.
For SCLC, limited-stage treatment commonly involves chemotherapy with chest radiation. Extensive-stage treatment often involves chemotherapy and immunotherapy. The precise plan depends on the clinical setting and current guidelines.
Where Can Lung Cancer Spread?
Common sites include the brain, bones, liver, adrenal glands and the opposite lung. A tumor found in the liver that originated in the lung is usually called metastatic lung cancer, not primary liver cancer. Not every suspicious scan finding is a metastasis.
What Influences Prognosis?
Prognosis is influenced by stage, cancer subtype, general health, ability to carry out everyday activities, tumor biomarkers, treatment response and whether treatment can be given with curative intent.
Population averages cannot predict one person’s outcome. Newer treatments, biomarker results, other medical conditions and individual treatment response all matter.
Can Lung Cancer Be Screened For?
Low-dose CT screening can reduce lung cancer deaths among appropriately selected people at high risk, particularly those with substantial smoking histories. Screening is not recommended for everyone; eligibility depends on age, smoking exposure, local guidance and whether a person could benefit from treatment.
What Is Supported, and What Is Not?
Diagnosis confirmed by pathology, accurate staging, appropriate biomarker testing and evidence-based treatment selection improve clinical decision-making.
NSCLC and SCLC differ, and even tumors of the same type can require different treatments depending on stage and molecular features.
Ignoring persistent warning signs, self-treating with unproven cancer remedies or stopping prescribed therapy without medical advice can lead to avoidable harm. Discuss supplements and alternative approaches with the oncology team.
Questions to Ask Your Cancer Care Team
- What is my exact lung cancer type and subtype?
- What stage has been confirmed, and how was it established?
- Which molecular and PD-L1 tests are appropriate for my case?
- Is the treatment goal cure, disease control or symptom relief?
- Why is this treatment preferred over other options?
- What benefits, side effects and alternatives should I understand?
- Would multidisciplinary review or a clinical trial be appropriate?
- When and how will treatment response be assessed?
CancerSnoop Bottom Line
Accurate pathology, staging and appropriate biomarker testing guide care. Some early-stage cancers can be treated with the goal of cure. Advanced disease often requires treatment aimed at controlling cancer, extending life and maintaining quality of life. There is no single best treatment for every patient.
Scientific Sources
1. Non-Small Cell Lung Cancer Treatment (PDQ®) – Health Professional Version
National Cancer Institute. Evidence-based clinical summary of NSCLC staging and treatment.
2. Early and Locally Advanced Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guideline
European Society for Medical Oncology. Annals of Oncology. 2025. DOI: 10.1016/j.annonc.2025.08.003.
3. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Ninth Edition
International Association for the Study of Lung Cancer. Journal of Thoracic Oncology. DOI: 10.1016/j.jtho.2023.10.010.
Last reviewed: October 19, 2026.
CancerSnoop Note: This article provides evidence-based educational information. It does not diagnose cancer or recommend individual treatment. Cancer care decisions should be made with qualified healthcare professionals familiar with the patient’s medical history.
Original language: English.